BiotechTube
Iantrek

Iantrek

San Diego, United States· Est.
iantrekmed.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Iantrek is a private, clinical-stage medical device company developing innovative solutions for interventional glaucoma surgery. The company's core technology platform targets the uveoscleral outflow pathway, with its lead product, AlloFlo™ Uveo, already used in over 3,000 U.S. cases and supported by robust clinical data from the CREST study. Founded in 2018 and based in San Diego, Iantrek recently secured a $42 million Series C financing to support the commercial launch of its breakthrough therapy.

OphthalmologyGlaucoma

Technology Platform

Bio-interventional platform for ab-interno microsurgery, featuring a scleral allograft tissue (AlloFlo™ Uveo) and a specialized delivery instrument (AlloSert™ Uveo) designed to enhance uveoscleral outflow for glaucoma.

Opportunities

Iantrek addresses a large and growing glaucoma surgery market with a differentiated approach targeting the uveoscleral pathway, offering a potential best-in-class safety and efficacy profile.
The product's compatibility with cataract surgery and its use in over 3,000 cases provide a strong foundation for rapid commercial adoption.
Recent $42M Series C funding provides ample capital to execute its launch strategy.

Risk Factors

Key risks include commercial execution in a crowded market, the need for long-term real-world safety data, and the challenge of driving surgical adoption for a novel technique.
Reimbursement dynamics and competition from large, established medical device companies pose additional significant hurdles.

Competitive Landscape

Iantrek competes in the interventional glaucoma space against large players like Alcon, J&J (Sight Sciences), and Glaukos, as well as other MIGS-focused companies. Its primary differentiation is its exclusive focus on bio-reinforcement of the uveoscleral outflow pathway, a niche with limited direct competitors compared to the crowded trabecular meshwork and subconjunctival device markets.

More companies in Drug Delivery & Formulation →More companies in United States →